Announcement • Feb 03
LungLife AI, Inc. to Seek Approval from the Shareholders to Cancel the Admission of the Company's Ordinary Shares to Trading on AIM LungLife AI, Inc. proposed to seek to reengage with parties regarding the securing of a strategic partner for LungLife. However, in light of the cash runway available to the Company and the lack of interest in a fundraising, it has now become clear to the Board that the most appropriate course of action is for the Board to seek approval from the shareholders of the Company to cancel the admission of the Company's ordinary shares to trading on AIM in accordance with Rule 41 of the AIM Rules for Companies. A circular convening a general meeting of the Company to approve the proposed cancellation and providing further detail on the next steps will be published in due course and a further announcement will be made at that time. Announcement • Oct 27
LungLife AI, Inc. Announces Resignation of James Mccullough as Non-Executive Director LungLife AI, Inc. announced the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024. James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc. Following this resignation, the Board remains confident in its current composition, which continues to reflect a strong balance of skills, experience, and independence. At this time, the Board has no immediate plans to seek a replacement, as it believes the current structure, together with the Scientific Advisory Board, is well-positioned to support the company's ongoing growth and development and does not impact the composition and independence of its committees. New Risk • Aug 23
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$4.3m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (UK£3.99m market cap, or US$5.23m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Shareholders have been diluted in the past year (20% increase in shares outstanding). 
